Cardiomyopathy in MR image

Česká verzia

Authors: Lenka Křivková ¹; Věra Feitová ^1,2; Jiří Vaníček ^1,2
Authors place of work: Klinika zobrazovacích metod LF MU a FN u sv. Anny v Brně ¹; Mezinárodní centrum klinického výzkumu FN u sv. Anny v Brně ²
Published in the journal: Vnitř Lék 2016; 62(6): 467-473
Category: Reviews

Summary

The purpose of this article is to summarize some general information about the most common types of cardiomyopathies with an emphasis on a use of cardiac magnetic resonance imaging (CMR) in its diagnosis. Although characteristic CMR findings of the cardiomyopathy are generally revealed, the establishing of a clear diagnosis could be difficult. The assessment of structural myocardial abnormalities allows determination of the degree of changes in the myocardium and the prognosis of the disease. The wide range of information about the heart structure and function is feasible to achieve due to advanced techniques of magnetic resonance imaging and the imaging is not limited by acoustic windows as it is in case of echocardiography. The role of CMR in diagnostics of the cardiomyopathies tends to be increasingly important, cardiologists increasingly favour this examination and it is consequently becoming a standard part of a diagnostic algorithm.

Key words:
amyloidosis – cardiac magnetic resonance – cardiomyopathy – myocardial hypertrophy

Zdroje

1. Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29(2): 270–276.

2. Brtko M, Šťástek J, Vojáček J et al. Hypertrofická kardiomyopatie: současné možnosti léčby. Interv Akut Kardiol 2008; 7(3): 100–105.

3. Bogaert J, Dymarkowski S (eds) et al. Clinical cardiac MRI. 2nd ed. Springer: Beriln 2012: 1–28; 284–312. ISBN 978–3642230349.

4. Maron BJ. Hypertrophic Cardiomyopathy: A Systematic Review. JAMA 2002; 287(10): 1308–1320.

5. Wigle DE, Rakowski H, Kimball BP et al. Hypertrophic Cardiomyopathy Clinical Spectrum and Treatment. Circulation 1995; 92(7): 1680–1692.

6. Maron MS, Olivotto I, Zenovich AG et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outfl ow tract obstruction. Circulation 2006; 114(21): 2232–2239.

7. Maron MS, Hauser TH, Dobrow E et al. Right Ventricular Involvement in Hypertrophic Cardiomyopathy. Am J Cardiol 2007; 100(8): 1293–1298.

8. Spirito P, Bellone P, Harris KM et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(24): 1778–1785.

9. Pleva M, Ouředníček P. MRI srdce : praktické využití z pohledu kardiologa. Grada: Praha 2012: 47–49; 67–82. 978–80–247–3931–1.

10. Rickers C, Wilke NM, Jerosch-Herold M et al. Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy. Circulation 2005; 112(6): 855–861.

11. Aquaro GD, Positano V, Pingitore A et al. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2010; 12: 21. Dostupné z DOI: <http://dx.doi.org/10.1186/1532–429X-12–21>.

12. Green JJ, Berger JS, Kramer CM et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012; 5(4): 370–377.

13. Appelbaum E, Maron BJ, Adabaq S et al. Intermediate-signal-intensity late gadolinium enhancement predicts ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2012; 5(1): 78–85.

14. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2008; 51(14): 1369–1374.

15. Kasper EK, Agema WR, Hutchins GM et al. The causes of dilated cardiomyopathy: A clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol 1994; 23(3): 586–590.

16. Francone M. Role of Cardiac Magnetic Resonance in the Evaluation of Dilated cardiomyopathy: Diagnostic Contribution and Prognostic Significance. ISRN Radiology 2014: 365404. Dostupné z DOI: http://dx.doi.org/10.1155/2014/365404.

17. Karamitsos TD, Francis JM, Myerson S et al. CMR in Heart Failure. J Am Coll Cardiol 2009; 54(15): 1407–1424.

18. McCrohon JA, Moon JCC, Prasad SK et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108(1): 54–59.

19. Assomull RG, Prasad SK, Lyne J et al. Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. J Am Coll Cardiol 2006; 48(10): 1977–1985.

20. Riedel M. Konstriktivní perikarditida. Kardiologická revue 2003; 5(2): 69–75.

21. Hancock EW Differential diagnosis of restrictive cardiomyopathy and constrictive pericarditis. Heart 2001; 86(3): 343–349.

22. Banypersad SM, Moon JC, Whelan C. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc 2012; 1(2): e000364. Dostupné z DOI: http://dx.doi.org/10.1161/JAHA.111.000364.

23. Maceira AM, Jayshree J, Prasad SK et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111(2): 186–193.

24. Kuchynka P, Paleček T, Šimek S et al. Izolovaná forma srdeční amyloidózy v podobě počínající infiltrativní kardiomyopatie bez restriktivní fyziologie. Vnitř Lék 2008; 54(10): 1010–1013.

25. Vogelsberg H, Mahrholdt H, Deluigi CC et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51(10): 1022–1030.

26. Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Proposed Modification of the Task Force Criteria. Circulation 2010; 121(13): 1533–1541.

27. Neužil P, Syrůček M, Balák J et al. Izolovaná arytmogenní kardiomyopatie levé komory se známkami tukové přestavby. Praktický lékař 2007; 87(8): 496–500.

28. Haman L. Arytmogenní kardiomyopatie pravé komory. Intervenční a akutní kardiologie 2014; 13(2): 87–91.

29. 29.Vondrak K. Izolovaná nonkompaktní kardiomyopatie: souhrnný článek s kazuistickým příkladem. Vnitř Lék 2014; 60(2): 164–170.

30. Jacquier A, Thuny F, Jop B et al. Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction. Eur Heart J 2010; 31(9): 1098–1104.

31. Weiford BC, Subbarao VD, Mulhern KM. Noncompaction of the Ventricular Myocardium. Circulation 2004; 109(24): 2965–2971.

32. Virtová R, Kubánek M, Šramko M et al. Isolated non-compaction cardiomyopathy: A review. Cor et Vasa 2013; 55(3): e236-e241. Dostupné z WWW: http://www.sciencedirect.com/science/article/pii/S001086501200118X.

33. Petersen SE, Selvanayagam JB, Wiesmann F et al. Left Ventricular Non-Compaction Insights From Cardiovascular Magnetic Resonance Imaging. J Am Coll Cardiol 2005; 46(1): 101–105.

34. Aschermann M, Aschermann O. Tako tsubo kardiomyopatie. Vnitř Lék 2009; 55(9): 792–796.

35. Naruse Y, Sato A, Kasahara K et al. The clinical impact of late gadolinium enhancement in Takotsubo cardiomyopathy: serial analysis of cardiovascular magnetic resonance images. J Cardiovasc Magn Reson 2011; 13: 67–76. Dostupné z DOI: <http://dx.doi.org/10.1186/1532–429X-13–67>.

36. Vopelková J, Veselka J. Tako-tsubo syndrom – nový přírůstek do rodiny akutních stavů v kardiologii: aktuální sdělení. Vnitř Lék 2006; 52(11): 1066–1068.